Mary Kay Fenton compensation by year
Cullinan Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $333,808 | $512,325 |
| Bonus | $0 | $0 |
| Stock awards | $0 | $565,800 |
| Option awards | $3,598,260 | $744,780 |
| Non-equity incentive | $174,581 | $211,898 |
| Pension and deferred compensation | $0 | $0 |
| All other | $35,764 | $44,034 |
| Total | $4,142,413 | $2,078,837 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cullinan Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001193125-26-183465, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Cullinan Therapeutics, Inc. filed document, accession 0001193125-26-183465. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 60,000 | $621,000 | — |
| Option | 116,667 | — | $27.12 |
| Option | 94,984 | — | $9.43 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Cullinan Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed April 28, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-30 | Grant or award | — | 1,541 | $8.60 | 127,921 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Cullinan Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Nadim Ahmed | President and Chief Executive Officer | $5,100,006 |
| Jeffrey Jones | Chief Medical Officer | $2,221,578 |
| Mary Kay Fenton · this page | Chief Financial Officer | $2,078,837 |
Mary Kay Fenton's compensation dossier, Cullinan Therapeutics
You have read Mary Kay Fenton's totals and holdings. The dossier adds each equity grant Cullinan Therapeutics disclosed for Mary Kay Fenton and Cullinan Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Cullinan Therapeutics compensation record
free company briefThis page is one person within Cullinan Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Cullinan Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cullinan Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order CGEM
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.